PE20010389A1 - Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana - Google Patents

Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana

Info

Publication number
PE20010389A1
PE20010389A1 PE2000000644A PE0006442000A PE20010389A1 PE 20010389 A1 PE20010389 A1 PE 20010389A1 PE 2000000644 A PE2000000644 A PE 2000000644A PE 0006442000 A PE0006442000 A PE 0006442000A PE 20010389 A1 PE20010389 A1 PE 20010389A1
Authority
PE
Peru
Prior art keywords
alkyl
day
migrana
caffeine
inhibitor
Prior art date
Application number
PE2000000644A
Other languages
English (en)
Inventor
George Harry Sands
Wilma Marcia Harrison
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010389A1 publication Critical patent/PE20010389A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE a)UN AGONISTA DEL RECEPTOR 5HT1 TAL COMO ELETRIPTAN, RIZATRIPTAN, ZOLMITRIPTAN, SUMATRIPTAN, NARATRIPTAN UTILIZANDOSE 0,05 mg/DIA A 100 mg/DIA; b)CAFEINA UTILIZANDOSE 15 mg/DIA A 200 mg/DIA; c)UN INHIBIDOR DE CICLOOXIGENASA 2 TAL COMO i)UN DERIVADO DE INDOL DE FORMULA I; DONDE R1 ES H, ALQUILO C1-C4; R2 ES C(=L`)R3, SO2R4; Y ES UN ENLACE, ALQUILENO C1-C4; L Y L' SON O, S; Q ES ALQUILO C1-C6, CICLOALQUILO C3-C7, FENILO, NAFTILO, MONOCICLO AROMATICO DE 5-6 MIEMBROS; R3 ES OR6, NR7R8, N(OR1)R7, GRUPO a; Z ES UN ENLACE, O, S, NR5; R4 ES ALQUILO C1-C6, ENTRE OTROS; R5 ES ALQUILO C1-C4; R6 ES ALQUILO C1-C4, CICLOALQUILO C3-C7, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; X ES HALO, ALQUILO C1-C4, ENTRE OTROS; n ES 0-3; r ES 1-3; ii)UN COMPUESTO XX; DONDE A ES UN HETEROCICLO DE 5 MIEMBROS, CARBOCICLO DE 5 MIEMBROS; R1 ES ARILO, HETEROARILO; R2 ES ALQUILO C1-4; R3, R4, R5 SON H, HALO, ALQUILO C1-C4; R6 Y R7 SON H, HALO, ALQUILO, ENTRE OTROS, DE PREFERENCIA (2-BENZOIL-6-CLORO-1H-3-IL)-ACETICO, ACIDO 6-CLORO-2-(2-METILBENZOIL)-1H-1H-INDOL-3-IL]ACETICO, ENTRE OTROS; UTILIZANDOSE DE 10/DIA mg A 300 mg/DIA. LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA MIGRANA
PE2000000644A 1999-06-30 2000-06-27 Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana PE20010389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14171599P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
PE20010389A1 true PE20010389A1 (es) 2001-04-07

Family

ID=22496903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000644A PE20010389A1 (es) 1999-06-30 2000-06-27 Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana

Country Status (11)

Country Link
US (1) US6476042B1 (es)
EP (1) EP1064966A3 (es)
JP (1) JP2001039870A (es)
KR (1) KR20010049684A (es)
AU (1) AU4373600A (es)
CA (1) CA2312989A1 (es)
CO (1) CO5190664A1 (es)
HU (1) HUP0002509A3 (es)
IL (1) IL136960A0 (es)
PE (1) PE20010389A1 (es)
ZA (1) ZA200003236B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
US8680081B2 (en) 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
EP1575566B1 (en) 2002-12-26 2012-02-22 Pozen, Inc. Multilayer dosage forms containing naproxen and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US20040204475A1 (en) * 2003-04-11 2004-10-14 Humphrey Michael John Pharmaceutical combination
US20070196340A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
CA2545771A1 (en) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Migraine treatments including isovaleramide compounds and serotonin agonists
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
CN102088966B (zh) 2008-06-20 2015-06-10 阿尔法制药有限公司 药物制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
KR100229343B1 (ko) 1993-11-30 1999-11-01 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
DE4342568A1 (de) * 1993-12-14 1994-06-01 Paul Ralf Peter Coffeinhaltige Kaugummiware
CA2182950A1 (en) 1994-02-10 1995-08-17 David B. Reitz Substituted spiro compounds for the treatment of inflammation
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
KR100373622B1 (ko) 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
DK1007067T3 (da) 1996-10-21 2002-05-06 Eurovita As Farmaceutiske præparater indeholdende Parthenium integrifolium eller dele deraf eller en ekstrakt bestanddel deraf, anvendelsen af et sådant plantemateriale til fremstilling af ...
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ATE206921T1 (de) * 1997-07-03 2001-11-15 Pfizer Eletriptanhemisulfat und kaffein enthaltende pharmazeutische zusammenstellungen
US5994379A (en) 1998-02-13 1999-11-30 Merck Frosst Canada, Inc. Bisaryl COX-2 inhibiting compounds, compositions and methods of use
DE69922688T2 (de) 1998-11-02 2005-12-01 Merck & Co. Inc. Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
WO2000026216A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors

Also Published As

Publication number Publication date
CO5190664A1 (es) 2002-08-29
AU4373600A (en) 2001-01-04
HU0002509D0 (en) 2000-08-28
EP1064966A3 (en) 2003-01-08
EP1064966A2 (en) 2001-01-03
ZA200003236B (en) 2002-01-02
HUP0002509A3 (en) 2003-12-29
HUP0002509A2 (en) 2001-03-28
US6476042B1 (en) 2002-11-05
CA2312989A1 (en) 2000-12-30
IL136960A0 (en) 2001-06-14
KR20010049684A (ko) 2001-06-15
JP2001039870A (ja) 2001-02-13

Similar Documents

Publication Publication Date Title
PE20010389A1 (es) Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
PE20081658A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 y sus metodos de uso
ES2096639T3 (es) Derivados de benzofurano, benzotiofeno, indol o indolizina, su procedimiento de preparacion, asi como las composiciones que los contienen.
EA200600348A1 (ru) Новые соединения
NO166129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler.
TW346485B (en) Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
HUP0102563A2 (hu) Indolszármazékok és alkalmazásuk rosszindulatú és egyéb, patológiás sejtproliferáción alapuló megbetegedések kezelésére
AR037222A1 (es) Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion
ATE168102T1 (de) 1,4-benzodiazepinderivate und ihre verwendung als cck-modulatoren
CA2271085A1 (fr) Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
BR9710230A (pt) Derivados de indol para o tratamento de osteoporose
ES2178451T3 (es) Derivados de benzoxadiazoles, benzotiadiazoles, benzotriazoles y quinoxalinas.
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
DE10199016I2 (de) Indol derivate zur Behandlung von Migraene
PE20090112A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
RS20060502A (en) (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor
NZ505060A (en) 2-Aryl or heterocyclyl substituted indole derivatives useful for the treatment of osteoporosis
AR054329A1 (es) Compuestos no esteroideos moduladores de los receptores de glucocorticoides
PE20010128A1 (es) Composicion de un agonista del receptor 5ht1 y un inhibidor de la cox-2 para el tratamiento de la migrana
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
PE20010134A1 (es) Uso de agonistas de receptores 5ht1 y un inhibidor de la cox-2 para el tratamiento de la migrana

Legal Events

Date Code Title Description
FD Application declared void or lapsed